PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Follow-Up Questions
What is PolyPid Ltd (PYPD)'s P/E Ratio?
The P/E ratio of PolyPid Ltd is N/A
Who is the CEO of PolyPid Ltd?
Ms. Dikla Akselbrad is the Chief Executive Officer of PolyPid Ltd, joining the firm since 2014.
What is the price performance of PYPD stock?
The current price of PYPD is 3.48, it has decreased 0.33% in the last trading day.
What are the primary business themes or industries for PolyPid Ltd?
PolyPid Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is PolyPid Ltd market cap?
PolyPid Ltd's current market cap is $54.5
Is PolyPid Ltd a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for PolyPid Ltd, including 2 strong buy, 7 buy, 1 hold, 0 sell, and 2 strong sell
